Global pharma major Lupin Limited (Lupin) today announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the USFDA.
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals and indicated:
– to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD)
– to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.
Rivaroxaban Tablets USP, 2.5 mg (RLD Xarelto®) had estimated annual sales of USD 446 million in the U.S. (IQVIA MAT January 2025).
Yes, this is an official hiring notice from Aurobindo Pharma. The details of the upcoming…
Ready to Power Up Your Pharma Career? Halewood Laboratories Private Limited Your future starts with…
WALK-IN INTERVIEW | GRANULES LIFE SCIENCES 🚨 Granules Life Sciences – Shamirpet We welcome experienced…
WALK-IN INTERVIEW | QA HEAD – PHARMA 🚨 We are hiring for a QA Head…
Dr.Reddys Laboratories Ltd Walk-in Interview.Dr.Reddys Laboratories Ltd Notification full details below.Interested and eligible candidates can…
West-Coast Pharmaceutical Works Ltd. is hosting a walk-in interview for its Quality Assurance (QA) team.…